Insulin Lispro 100 units

Insulin lispro 100 units/mL is a rapid-acting insulin analogue used to control blood glucose in people with diabetes mellitus who require insulin therapy. It is produced using recombinant DNA technology and has a small structural difference from naturally occurring human insulin that allows it to be absorbed more rapidly after subcutaneous injection. By binding to insulin receptors, it helps glucose move from the bloodstream into muscle and fat cells and reduces glucose production by the liver. Its rapid onset of action makes it useful for controlling the rise in blood glucose associated with meals. The formulation contains 100 units of insulin lispro per millilitre and is available in product-specific presentations such as vials, cartridges, and prefilled pens. Depending on the approved product instructions, it can be administered under the skin shortly before a meal or immediately after eating. Certain formulations may also be administered intravenously under professional supervision or used in compatible insulin pumps. Insulin lispro may be used in type 1 or type 2 diabetes, alone as part of an insulin regimen or alongside longer-acting insulin and other appropriate treatments. Dosing must be individualized according to glucose measurements, food intake, physical activity, and clinical needs. Regular monitoring and education about low blood glucose are essential for safe use.

Insulin lispro was developed as a rapid-acting insulin analogue using recombinant DNA technology. Its amino-acid sequence differs slightly from human insulin, reducing the tendency of insulin molecules to form larger complexes after injection and allowing faster absorption. The United States Food and Drug Administration initially approved Humalog, an insulin lispro product, in 1996. The European Commission granted marketing authorization for Humalog in the European Union on 30 April 1996 following assessment by the European Medicines Agency. Insulin lispro 100 units/mL has since been supplied in several presentations, including vials, cartridges, and prefilled pens, with product availability varying by market. Clinical studies in people with type 1 and type 2 diabetes evaluated its ability to control post-meal glucose and its safety compared with regular human insulin. Current indications, approved ages, and permitted administration methods depend on the specific product and local prescribing information.

Insulin lispro 100 units/mL is used to improve blood glucose control in adults and children with diabetes mellitus who require insulin. In type 1 diabetes, it provides rapid-acting insulin coverage for meals and is generally used as part of a regimen that also provides basal insulin. In type 2 diabetes, it may be prescribed when additional insulin is needed to control blood glucose, either alongside longer-acting insulin or with other glucose-lowering treatments where appropriate. The formulation is particularly useful for managing post-meal increases in blood glucose. Depending on the specific product and clinical setting, insulin lispro may also be used in compatible continuous subcutaneous insulin infusion systems or administered intravenously by healthcare professionals. It is not intended to be used as a substitute for necessary basal insulin in type 1 diabetes, and it is not a standalone treatment for diabetic ketoacidosis.

Insulin lispro 100 units/mL is administered according to the specific product instructions and an individualized prescription. For subcutaneous use, it is generally injected into the abdomen, thigh, upper arm, or buttocks within 15 minutes before a meal or immediately after a meal. It may be prescribed at mealtimes with longer-acting insulin or as part of an appropriate insulin regimen. The dose depends on blood glucose results, carbohydrate intake, physical activity, previous insulin use, illness, and individual insulin sensitivity. Some product presentations are suitable for use in compatible insulin pumps, while intravenous administration is restricted to appropriate clinical settings and approved formulations. Patients should rotate injection sites and follow the product-specific instructions for the vial, cartridge, pen, or pump. The dose should not be changed or treatment stopped without medical guidance. Regular glucose monitoring is needed to guide adjustments and reduce the risk of hypoglycaemia.

The most common side effect of insulin lispro is hypoglycaemia, or low blood glucose. Symptoms may include sweating, trembling, hunger, dizziness, headache, palpitations, irritability, or difficulty concentrating. Other possible effects include weight gain, injection-site redness or discomfort, itching, and changes in fatty tissue beneath the skin when injections are repeatedly given in the same area. Temporary swelling may occur in some patients, particularly after changes in insulin treatment or improvement in glucose control. The likelihood of side effects can be influenced by dose, meal timing, exercise, alcohol use, kidney or liver function, and other medicines. Patients should follow their monitoring plan, learn how to recognize and treat low blood glucose, and discuss recurrent episodes or persistent injection-site reactions with their healthcare professional.

Severe hypoglycaemia can cause confusion, seizures, loss of consciousness, or life-threatening complications and requires urgent treatment. Insulin lispro can also cause hypokalaemia, or low blood potassium, which may be serious in susceptible patients. Rarely, severe allergic reactions can occur. Incorrect dosing, confusion between insulin products or concentrations, missed meals, unexpected physical activity, and changes in kidney or liver function can lead to dangerous changes in blood glucose. Insulin lispro should not be used during an active episode of hypoglycaemia or in patients with a known serious hypersensitivity to the product’s ingredients. Patients using insulin pumps require clear instructions for responding to interrupted insulin delivery, because inadequate insulin can rapidly lead to high blood glucose and diabetic ketoacidosis, particularly in type 1 diabetes. Treatment changes should be made under appropriate medical supervision, and urgent care should be sought for severe hypoglycaemia or signs of a serious allergic reaction.

Before treatment begins, clinicians should assess the patient’s diabetes history, current insulin regimen, glucose records, meal patterns, hypoglycaemia risk, and kidney and liver function. Insulin requirements may change during pregnancy, breastfeeding, acute illness, changes in weight, or alterations in diet and physical activity. Other glucose-lowering medicines may increase the risk of hypoglycaemia when combined with insulin lispro. Corticosteroids, some diuretics, thyroid hormones, sympathomimetic medicines, and certain antipsychotics may raise blood glucose or alter insulin requirements. Beta blockers can mask some warning signs of hypoglycaemia, while alcohol may increase or prolong the risk of low blood glucose. Patients should receive clear instructions on injection technique, meal coordination, glucose monitoring, and product-specific storage. Those using insulin pumps should understand pump operation and have a clinician-approved plan for delivery interruptions. Insulin pens, cartridges, syringes, and needles must be used according to the product instructions and must never be shared.

Confirm the insulin concentration, presentation, delivery device, and prescribed dose before dispensing or administration. Assess whether the patient needs basal insulin alongside mealtime insulin and explain that rapid-acting insulin lispro does not replace the full-day coverage provided by a basal insulin regimen when one is required. Provide practical education on meal timing, injection-site rotation, glucose monitoring, recognition and treatment of hypoglycaemia, and safe dose adjustment. Review glucose records when considering changes to treatment, particularly after changes in food intake, activity, illness, kidney or liver function, or concurrent medicines. For pump users, confirm device compatibility and reinforce the need for a plan in case insulin delivery is interrupted. Pharmacists should demonstrate correct pen or vial use, explain storage and expiry requirements, and help prevent mix-ups between insulin products or concentrations.